Ferozsons Partners with Gilead to Manufacture HIV Drugs

KARACHI: In a significant move for the pharmaceutical industry in Pakistan, Ferozsons Laboratories Ltd has announced a partnership with Gilead Sciences Ireland UC, a leading US-based biopharmaceutical company, to manufacture HIV drugs locally.

As per a notice submitted to the Pakistan Stock Exchange (PSX) on Thursday, Ferozsons has signed a non-exclusive voluntary license agreement with Gilead to produce and sell a licensed generic version of Lenacapavir. This agreement positions Ferozsons as one of the six global partners granted the license to produce this high-quality, generic version of the HIV treatment.

What Is Lenacapavir?

Lenacapavir is an innovative drug used in the treatment of HIV, known for its long-acting effects, making it a crucial component in managing the disease. Gilead’s decision to expand production to global partners like Ferozsons signifies the growing demand for accessible HIV treatment options worldwide. This partnership will ensure that affordable and high-quality generic HIV drugs are available to patients in Pakistan, helping to reduce the burden of the disease.

Strengthening Local Manufacturing

This collaboration between Ferozsons and Gilead also highlights the growing capacity of Pakistan’s pharmaceutical industry to manufacture critical medicines that meet international standards. By producing these drugs locally, Ferozsons aims to make HIV treatment more accessible to patients in Pakistan, reducing reliance on expensive imports and ensuring a steady supply of life-saving medications.

#Ferozsons #GileadSciences #HIVTreatment #PharmaNews #HealthcarePakistan #Lenacapavir #GenericMedicines #PharmaceuticalIndustry